Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.79
PDLI's Cash to Debt is ranked lower than
82% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. PDLI: 0.79 )
Ranked among companies with meaningful Cash to Debt only.
PDLI' s 10-Year Cash to Debt Range
Min: 0.25  Med: 1.11 Max: No Debt
Current: 0.79
Equity to Asset 0.41
PDLI's Equity to Asset is ranked lower than
77% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PDLI: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
PDLI' s 10-Year Equity to Asset Range
Min: -1.93  Med: 0.47 Max: 0.98
Current: 0.41
-1.93
0.98
Interest Coverage 13.93
PDLI's Interest Coverage is ranked lower than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 13.93 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s 10-Year Interest Coverage Range
Min: 4.85  Med: 15.35 Max: 9999.99
Current: 13.93
4.85
9999.99
F-Score: 4
Z-Score: 3.91
M-Score: 0.96
WACC vs ROIC
7.63%
64.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 93.60
PDLI's Operating margin (%) is ranked higher than
99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. PDLI: 93.60 )
Ranked among companies with meaningful Operating margin (%) only.
PDLI' s 10-Year Operating margin (%) Range
Min: -194.42  Med: -32.72 Max: 94.93
Current: 93.6
-194.42
94.93
Net-margin (%) 56.19
PDLI's Net-margin (%) is ranked higher than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. PDLI: 56.19 )
Ranked among companies with meaningful Net-margin (%) only.
PDLI' s 10-Year Net-margin (%) Range
Min: -215.32  Med: -20.37 Max: 59.61
Current: 56.19
-215.32
59.61
ROE (%) 92.06
PDLI's ROE (%) is ranked higher than
99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. PDLI: 92.06 )
Ranked among companies with meaningful ROE (%) only.
PDLI' s 10-Year ROE (%) Range
Min: -35.5  Med: -5.74 Max: 1166.18
Current: 92.06
-35.5
1166.18
ROA (%) 34.59
PDLI's ROA (%) is ranked higher than
98% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. PDLI: 34.59 )
Ranked among companies with meaningful ROA (%) only.
PDLI' s 10-Year ROA (%) Range
Min: -17.78  Med: -1.80 Max: 77.05
Current: 34.59
-17.78
77.05
ROC (Joel Greenblatt) (%) 4364.69
PDLI's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. PDLI: 4364.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PDLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106.3  Med: 29.20 Max: 673588.24
Current: 4364.69
-106.3
673588.24
Revenue Growth (3Y)(%) 18.10
PDLI's Revenue Growth (3Y)(%) is ranked higher than
76% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PDLI: 18.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PDLI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -88.7  Med: 16.30 Max: 997.9
Current: 18.1
-88.7
997.9
EBITDA Growth (3Y)(%) 17.20
PDLI's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. PDLI: 17.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PDLI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 5.10 Max: 853.4
Current: 17.2
0
853.4
EPS Growth (3Y)(%) 18.40
PDLI's EPS Growth (3Y)(%) is ranked higher than
76% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. PDLI: 18.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PDLI' s 10-Year EPS Growth (3Y)(%) Range
Min: -89.5  Med: 4.15 Max: 798.3
Current: 18.4
-89.5
798.3
» PDLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PDLI Guru Trades in Q2 2014

Jim Simons 12,896,754 sh (+8.75%)
First Eagle Investment 2,800 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones 50,600 sh (-38.59%)
Joel Greenblatt 789,804 sh (-52.58%)
» More
Q3 2014

PDLI Guru Trades in Q3 2014

Paul Tudor Jones 125,900 sh (+148.81%)
Jim Simons 13,745,892 sh (+6.58%)
First Eagle Investment 2,800 sh (unchged)
Joel Greenblatt 25,997 sh (-96.71%)
» More
Q4 2014

PDLI Guru Trades in Q4 2014

Joel Greenblatt 183,003 sh (+603.94%)
First Eagle Investment 2,800 sh (unchged)
Jim Simons 11,771,000 sh (unchged)
Jim Simons 11,771,000 sh (-14.37%)
Paul Tudor Jones 68,300 sh (-45.75%)
» More
Q1 2015

PDLI Guru Trades in Q1 2015

James Barrow 262,299 sh (New)
Joel Greenblatt 3,365,474 sh (+1739.03%)
Paul Tudor Jones 118,200 sh (+73.06%)
Jim Simons 11,971,554 sh (+1.70%)
First Eagle Investment 2,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about PDL BioPharma Inc

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC
According to GuruFocus list of 3-year lows, Apollo Education Group Inc, PDL BioPharma Inc, Thompson Creek Metals Co Inc, Allot Communications Ltd, and Electro Rent Corp have all reached their 3-year lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 2.99
PDLI's P/E(ttm) is ranked higher than
95% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. PDLI: 2.99 )
Ranked among companies with meaningful P/E(ttm) only.
PDLI' s 10-Year P/E(ttm) Range
Min: 2.99  Med: 5.54 Max: 24.65
Current: 2.99
2.99
24.65
Forward P/E 10.20
PDLI's Forward P/E is ranked higher than
87% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. PDLI: 10.20 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 3.00
PDLI's PE(NRI) is ranked higher than
96% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. PDLI: 3.00 )
Ranked among companies with meaningful PE(NRI) only.
PDLI' s 10-Year PE(NRI) Range
Min: 3.05  Med: 5.44 Max: 61.6
Current: 3
3.05
61.6
P/B 2.06
PDLI's P/B is ranked higher than
79% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. PDLI: 2.06 )
Ranked among companies with meaningful P/B only.
PDLI' s 10-Year P/B Range
Min: 1.61  Med: 3.42 Max: 38.49
Current: 2.06
1.61
38.49
P/S 1.67
PDLI's P/S is ranked higher than
90% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. PDLI: 1.67 )
Ranked among companies with meaningful P/S only.
PDLI' s 10-Year P/S Range
Min: 1.67  Med: 3.57 Max: 15.87
Current: 1.67
1.67
15.87
PFCF 6.86
PDLI's PFCF is ranked higher than
96% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. PDLI: 6.86 )
Ranked among companies with meaningful PFCF only.
PDLI' s 10-Year PFCF Range
Min: 4.53  Med: 10.76 Max: 388.73
Current: 6.86
4.53
388.73
POCF 3.42
PDLI's POCF is ranked higher than
98% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. PDLI: 3.42 )
Ranked among companies with meaningful POCF only.
PDLI' s 10-Year POCF Range
Min: 3.42  Med: 6.58 Max: 80.48
Current: 3.42
3.42
80.48
EV-to-EBIT 1.89
PDLI's EV-to-EBIT is ranked higher than
92% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. PDLI: 1.89 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s 10-Year EV-to-EBIT Range
Min: -54.9  Med: 4.00 Max: 508
Current: 1.89
-54.9
508
PEG 0.16
PDLI's PEG is ranked higher than
99% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. PDLI: 0.16 )
Ranked among companies with meaningful PEG only.
PDLI' s 10-Year PEG Range
Min: 0.13  Med: 0.41 Max: 45.75
Current: 0.16
0.13
45.75
Shiller P/E 4.05
PDLI's Shiller P/E is ranked higher than
96% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.33 vs. PDLI: 4.05 )
Ranked among companies with meaningful Shiller P/E only.
PDLI' s 10-Year Shiller P/E Range
Min: 4.05  Med: 8.69 Max: 105.83
Current: 4.05
4.05
105.83
Current Ratio 1.46
PDLI's Current Ratio is ranked lower than
81% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PDLI: 1.46 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s 10-Year Current Ratio Range
Min: 0.26  Med: 6.36 Max: 76.07
Current: 1.46
0.26
76.07
Quick Ratio 1.46
PDLI's Quick Ratio is ranked lower than
77% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. PDLI: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s 10-Year Quick Ratio Range
Min: 0.26  Med: 6.28 Max: 76.07
Current: 1.46
0.26
76.07
Days Sales Outstanding 38.97
PDLI's Days Sales Outstanding is ranked higher than
71% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. PDLI: 38.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s 10-Year Days Sales Outstanding Range
Min: 0.19  Med: 0.90 Max: 44.03
Current: 38.97
0.19
44.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 10.58
PDLI's Dividend Yield is ranked higher than
98% of the 218 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PDLI: 10.58 )
Ranked among companies with meaningful Dividend Yield only.
PDLI' s 10-Year Dividend Yield Range
Min: 2.26  Med: 7.73 Max: 10.58
Current: 10.58
2.26
10.58
Dividend Payout 0.31
PDLI's Dividend Payout is ranked higher than
66% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.37 vs. PDLI: 0.31 )
Ranked among companies with meaningful Dividend Payout only.
PDLI' s 10-Year Dividend Payout Range
Min: 0.24  Med: 0.42 Max: 0.6
Current: 0.31
0.24
0.6
Yield on cost (5-Year) 10.58
PDLI's Yield on cost (5-Year) is ranked higher than
98% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.42 vs. PDLI: 10.58 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PDLI' s 10-Year Yield on cost (5-Year) Range
Min: 2.26  Med: 7.73 Max: 10.49
Current: 10.58
2.26
10.49
Share Buyback Rate 0.80
PDLI's Share Buyback Rate is ranked higher than
95% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. PDLI: 0.80 )
Ranked among companies with meaningful Share Buyback Rate only.
PDLI' s 10-Year Share Buyback Rate Range
Min: 89.4  Med: -5.50 Max: -958.2
Current: 0.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.11
PDLI's Price/Tangible Book is ranked higher than
53% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. PDLI: 5.11 )
Ranked among companies with meaningful Price/Tangible Book only.
PDLI' s 10-Year Price/Tangible Book Range
Min: 0.86  Med: 3.31 Max: 47.2
Current: 5.11
0.86
47.2
Price/Projected FCF 0.56
PDLI's Price/Projected FCF is ranked higher than
97% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. PDLI: 0.56 )
Ranked among companies with meaningful Price/Projected FCF only.
PDLI' s 10-Year Price/Projected FCF Range
Min: 0.64  Med: 3.20 Max: 90.83
Current: 0.56
0.64
90.83
Price/Median PS Value 0.47
PDLI's Price/Median PS Value is ranked higher than
86% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. PDLI: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
PDLI' s 10-Year Price/Median PS Value Range
Min: 0.58  Med: 2.60 Max: 26.78
Current: 0.47
0.58
26.78
Price/Peter Lynch Fair Value 0.12
PDLI's Price/Peter Lynch Fair Value is ranked higher than
97% of the 40 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. PDLI: 0.12 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PDLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.15  Med: 0.32 Max: 2.65
Current: 0.12
0.15
2.65
Price/Graham Number 0.79
PDLI's Price/Graham Number is ranked higher than
96% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PDLI: 0.79 )
Ranked among companies with meaningful Price/Graham Number only.
PDLI' s 10-Year Price/Graham Number Range
Min: 0.58  Med: 2.67 Max: 117.29
Current: 0.79
0.58
117.29
Earnings Yield (Greenblatt) (%) 53.06
PDLI's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PDLI: 53.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PDLI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 22.90 Max: 53.06
Current: 53.06
0.2
53.06
Forward Rate of Return (Yacktman) (%) 36.70
PDLI's Forward Rate of Return (Yacktman) (%) is ranked higher than
84% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.59 vs. PDLI: 36.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PDLI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -8.7  Med: 1.70 Max: 44.3
Current: 36.7
-8.7
44.3

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 570 201 62
EPS($) 2.00 0.56 0.03
EPS without NRI($) 2.00 0.56 0.03

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PDL.Germany,
PDL BioPharma Inc was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. It's U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri and Actemra. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company's licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.
» More Articles for PDLI

Headlines

Articles On GuruFocus.com
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC May 17 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PDL BioPharma, Oct 17 2014 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against PDL BioPharma Inc Oct 15 2014 
Hot Picks with High Yields Jul 23 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PDLI May 12 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
FV 22 MSN 10 Apr 19 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 

More From Other Websites
Who Really Won in the PDL and Ariad Royalty Deal? Jul 29 2015
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with... Jul 29 2015
PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals Jul 29 2015
PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jul 29 2015
PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals Jul 29 2015
PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 Jul 28 2015
PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 Jul 28 2015
Buy PDL BioPharma For Strong Upside and High Dividend Yield Jul 21 2015
PDL BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 30 2015
PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications Jun 29 2015
PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications Jun 29 2015
PDL BIOPHARMA, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Jun 29 2015
PDL BioPharma to Present at the Nasdaq 32nd Investor Program Jun 25 2015
PDL BioPharma to Present at the Nasdaq 32nd Investor Program Jun 25 2015
PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Jun 24 2015
PDL BioPharma Appoints Steffen Pietzke as Controller and Chief Accounting Officer Jun 24 2015
PDL BioPharma Appoints Steffen Pietzke as Controller and Chief Accounting Officer Jun 24 2015
5 Biotech Stocks to Trade for Gains Jun 23 2015
PDL BioPharma Completes Regular Quarterly Dividend Payment Jun 15 2015
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK